HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetics tallow derivative use sanctioned regardless of countries' BSE status by FDA cmte.

This article was originally published in The Rose Sheet

Executive Summary

TALLOW DERIVATIVE USE REGARDLESS OF COUNTRY's BSE STATUS RECOMMENDED narrowly by FDA's Transmissible Spongiform Encephalopathies Advisory Committee. At a meeting in Bethesda, Md. April 15-16, the committee voted 6-5 to allow sourcing of tallow derivatives in cosmetics, food, nutritional supplements and drugs "from any country, irrespective of BSE status," according to Committee Chairman Paul Brown, MD, National Institute of Neurological Disorders & Stroke. The panel's recommendation would reverse current FDA guidelines, which have established that bovine source materials for the manufacturing of tallow derivatives should not come from countries where cattle have been infected with BSE. The committee's proposal will be taken under advisement by FDA.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS005329

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel